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Abstract
Transdermal drug delivery systems have become an intriguing research topic in pharmaceutical technology area and one of 
the most frequently developed pharmaceutical products in global market. The use of these systems can overcome associated 
drawbacks of other delivery routes, such as oral and parenteral. The authors will review current trends, and future applications 
of transdermal technologies, with specific focus on providing a comprehensive understanding of transdermal drug delivery 
systems and enhancement strategies. This article will initially discuss each transdermal enhancement method used in the 
development of first-generation transdermal products. These methods include drug/vehicle interactions, vesicles and particles, 
stratum corneum modification, energy-driven methods and stratum corneum bypassing techniques. Through suitable design 
and implementation of active stratum corneum bypassing methods, notably microneedle technology, transdermal delivery 
systems have been shown to deliver both low and high molecular weight drugs. Microneedle technology platforms have 
proven themselves to be more versatile than other transdermal systems with opportunities for intradermal delivery of drugs/
biotherapeutics and therapeutic drug monitoring. These have shown that microneedles have been a prospective strategy for 
improving transdermal delivery systems.
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Introduction
Transdermal drug delivery systems
Innovation in drug delivery systems is a key strategy employed 
to improve the bioavailability of active pharmaceutical 
ingredients (APIs). To date, oral delivery systems remain 
the most preferable method for administrating API due to the 
benefits offered, such as dosage form variety, painless ease 
of administration, convenience, self-administration, high 
safety, and patient compliance [1]. Despite these advantages, 
oral delivery systems have some limitations such as poor 
drug stability in the gastrointestinal tract  and subjection to 
first pass metabolism. For instance, there is a possibility of 
drug degradation caused by enzymatic reaction or exposure 
to the acidic environment in the stomach [2]. Moreover, the 
solubility issues of drugs in the intestinal fluid and their 
permeability through the intestinal membrane may act as rate 
limiting steps in drug absorption, causing low bioavailability 
[3]. These drawbacks are routinely observed in the delivery 
of peptide or protein-based drugs [2]. As a result, intravenous 
(IV) injection is designated as one of the most promising 
delivery system for proteinaceous drugs, as it can achieve 
up to 100% bioavailability, accurate dosing and hepatic 
metabolism avoidance [4]. It is not surprising, however, that 
the IV administration route has some potential disadvantages, 
for example, it is an invasive delivery method, causing 
pain, low patient compliance, and sharps waste disposal 
considerations add significant costs [1, 5]. With a view to 
potentially overcoming some of these disadvantages, the 
transdermal route has been explored as another prospective 
route for enhancing delivery of peptide drugs [6].
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Transdermal drug delivery systems use the skin as the 
drug administration site [7]. The administered drug is 
absorbed into the systemic circulation via blood vessels 
in the skin and then circulates around the body [8]. 
Transdermal drug delivery systems offer some advantages 
for patients, such as being less invasive (some methods 
are entirely noninvasive), first-pass metabolism avoidance, 
ease of application and administration, no need for 
expert personnel, and the potential to reduce frequency 
of administration [9, 10]. Additionally, this technology 
has been used for the delivery of different varieties of 
drugs, both hydrophilic and hydrophobic  compounds. 
The benefits documented above have garnered interest 
from pharmaceutical researchers to develop and explore 
transdermal drug delivery systems, particularly in 
modifying or breaching the stratum corneum to enhance 
drug permeation through the skin. A comparison of the 
three different routes of drug administration detailed herein 
is summarised in Fig. 1.
Skin
Skin is the first line of protection for the body from the 
external environment. It has an area of approximately 
1.5–2.0  m2 and accounts for 15% of the total body mass of 
an adult person [11]. Skin, as the largest organ, functions 
to protect the body from external disturbances, including 
physical, mechanical and chemical assault [12]. Moreover, 
due to the abundance of melanin, the skin also protects 
the human body from ultraviolet (UV) radiation from the 
sun [13]. Another important function of the skin is the 
maintenance of homeostasis via the thermoregulation 
system [14]. Sweating is one such thermoregulation 
mechanism performed by human skin [15]. Skin is also 
responsible for the excretion of several substances, such as 
xenobiotics, excessive lipids, sodium chloride, urea, uric 
acid, ammonia and lipid [16, 17]. In addition, researchers 
have been using the skin as the main absorption site 
for various kinds of drugs, both for local and systemic 
Fig. 1  Comparison of three different routes of drug administration: oral, intravenous injection and transdermal
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delivery as a consequence of the many blood capillaries 
residing in the dermis [7]. A detailed anatomy of the skin 
is presented in Fig. 2. The outermost layer of human skin 
is the epidermis, approximately 50–100 µm, dependent on 
where it is on the body [18].
Specifically, the epidermis consists of five different 
layers, illustrated in Fig. 3, that function in the mechanism 
of skin regeneration. The stratum corneum (SC), the 
most superficial layer of the epidermis, has a thickness of 
10–20 µm, consisting of 15–30 corneocyte cell layers. This 
layer regenerates every 4 weeks [19, 20]. The SC is made up 
of keratin proteins that comes from dead keratinocyte cells 
in the deeper layers, in a process termed cornification and, 
hence it is also known as a ‘horny layer’ [21]. Furthermore, 
SC is also composed of lipids, such as ceramides (30–40%) 
[22, 23], cholesterols, cholesterols esters, free fatty acids, 
Fig. 2  Schematic illustration of the anatomy of the skin
Fig. 3  Schematic representation 
of epidermis layer of human 
skin
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squalene, wax esters and triglycerides [12, 24]. Below the 
SC, there is a clear and thin layer of skin, namely stratum 
lucidum. The stratum lucidum consists of 2–3 layers of 
keratinocyte cells and is found only in digits, palms and 
soles [25]. The dead corneocytes of the SC are brought up 
from this layer.
The next layer under the stratum lucidum is the stratum 
granulosum. In this layer, the cells have a thicker membrane 
compared to the first two layers. The granulosum originates 
from granules within the living cells which are formed by 
the accumulation of keratohyalin, a protein structure found 
in the granules [26]. The stratum spinosum, an epidermal 
layer under the stratum granulosum, consists of 8–10 layers 
of keratinocytes [25]. The presence of cell connectors, 
namely desmosomes, between the cells causes this layer to 
be called the ‘spiny’ layer (stratum spinosum) [27]. Antigen 
presenting cells, known as Langerhans cells, are found in 
this layer [28]. These dendritic cells have a responsibility 
to engulf bacteria or exogenous particles and damaged 
cells by phagocytosis [29]. Finally, the deepest layer of the 
epidermal skin is the stratum basale which directly contacts 
the dermis via interconnecting collagen fibers. In the stratum 
basale, cells proliferate and become primary cells for 
keratinocytes that are present in the upper epidermal layers 
[30]. Merkel cell, a functional cell of the sensory systems, 
and melanocytes are found in this layer [31, 32].
Underlying the epidermis, the second layer of skin in the 
integumentary system is the dermis. There are two layers 
in the dermis, termed the papillary and reticular layers 
[25]. Specifically, adipocytes, blood vessels and lymphatic 
capillaries are found in the papillary layer of the dermis [33]. 
The reticular layer is much denser than the papillary layer, 
due to the high content of collagen fibers [34], affording it 
elasticity for functioning in movement. The dermal layer 
plays a key role in immune function, due to the presence 
of phagocytes, fibroblasts, leucocytes and mast cells [35]. 
Moreover, there are an abundance of hair follicles, sebaceous 
and sweat glands in the dermis, as a consequence of its role 
in sweating and sebum secretion mechanisms [36].
Underlying the dermis is the deepest skin layer, 
the hypodermis. The hypodermis, also known as the 
subcutaneous layer or the superficial fascia, functions 
as a connecting tissue between skin, muscle and bones 
and as a result this layer is rich in proteoglycans and 
glycosaminoglycans [37]. Furthermore, an abundance of 
adipose tissue in the hypodermis provides thermal insulation 
to keep the body warm [38].
Drug absorption via the skin
The skin is a potential site for drug absorption, due to 
the large surface area of this organ [39]. Following the 
application of drug-containing dosage forms onto the skin, 
drug will be released into the skin. However, the absorption 
of drug through the skin is very challenging, because there is 
the first barrier that has to be passed, the SC [8]. Structurally, 
the SC is composed of dead keratinocytes which, together 
the ceramide lipid component, form a dense structure 
which is known as a ‘brick-and-mortar’ arrangement [40, 
41]. The ‘brick’ component of the SC is keratin, an acidic 
or basic to neutral protein product of keratinocytes, while 
the ‘mortar’ is comprised of lipids. The keratinocytes are 
connected to each other by glycoprotein desmosomes, 
termed corneodesmosomes [42]. In order for administered 
drugs to be absorbed into the circulation, they must first 
permeate into the skin via this molecular architecture.
Generally, drug absorption from the skin via the SC can 
be distinguished into two pathways, transepidermal and 
transappendageal, as depicted in Fig. 4. The first pathway 
and the main absorption route is known as transepidermal 
Fig. 4  Schematic representation 
of transdermal drug delivery 
mechanisms
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[43]. The large surface area of the SC allows drug from 
transdermal patch to spread onto the skin surface and 
permeate into the cells (transcellular) [44] or interspaces 
between the cells (intercellular) [45]. The transepidermal 
route can be further subdivided into two pathways, namely 
transcellular and intercellular. In the transcellular route, 
drugs diffuse through SC cells during the absorption process. 
Therefore, drugs have to pass the membranes, which are 
composed of lipid bilayers [39]. This route is mostly 
taken by hydrophobic drugs because of the hydrophobic 
properties of lipid complex in the cell membranes of the 
SC [43]. The second route is the intercellular, in which 
the drugs have to diffuse through the lipid matrix of the 
intercellular space of residing keratinocytes in the SC [46]. 
Hydrophilic compounds or small molecules are transported 
via this route to reach vascular capillaries in the dermis 
[47]. The intercellular route is the dominant pathway for 
drug absorption and is primarily dependent on a specific 
balance of the drug molecule to be both sufficiently lipid 
and aqueous soluble. [48].
The second pathway of drug absorption from the skin is 
transappendageal [49] which is defined as drug delivery via 
hair follicles or sweat glands in the skin [50]. This route is 
necessary for the transport of polar or ionisable compounds 
and is useful for transport of large macromolecules which 
have problems passing through the epidermal cells due to 
the molecular size and different partition properties [43]. 
Nevertheless, the usage of this pathway is somewhat limited 
due to the smaller absorption area (~ 0.1% of total skin area), 
compared to that available for the transepidermal route [7]. 
Thus, researchers have developed methods to enhance drug 
absorption across the skin by modifying the structure of the 
SC, either chemically, physically or using combinations of 
these methods. In the following sections, the development of 
transdermal products and several technologies for enhancing 
drug absorption via the skin is discussed.
A brief history of transdermal products
The use of the skin for delivery of various kinds of 
compounds has been widely explored over many centuries 
[51]. The ancient populations in Africa administered 
different types of traditional plants and minerals topically 
for cosmetic purposes or treatment of skin diseases [52]. For 
example, in 4000 BC, ancient Egyptians had discovered the 
use of natural resources, such as henna, red ochers and kohl, 
for skin care and cosmetics [53]. In 1500 BC, they wrote 
hundreds of drugs and prescriptions on a papyrus paper, 
namely Ebers Papyrus (manuscript on medicine) [54]. One 
example of the information written in this book was the use 
of the tiger nut for covering skin wounds [54].
Some thousand years later, Galen, a Greek physician, 
introduced the first cold cream containing an emulsion of 
vegetable oil, beeswax and water for skin treatment [55, 56]. 
They used the cold cream for skin wounds, burns and joint 
pains, due to its perceived antimicrobial activity [57]. This 
invention was followed by the utilisation of bandages and 
plasters by ancient Chinese populations for administrating 
herbal mixtures [51]. They mixed herbal ingredients 
with natural rubber gums and applied the plaster to the 
skin for localised treatment. One of primary transdermal 
formulations found in the fifteenth century was Unguentum 
Hydrargyri, an ointment formulation containing mercury 
for treatment of syphilis [58, 59]. In 1880, a plaster-based 
formulation (‘gutta-percha plaster gauze’) was developed 
by a German pharmacist, Paul Carl Beiersdorf, to treat skin 
disorders [60]. One of the most well-known plasters was 
Emplastrum belladonnae made of Atropa belladonna leaves 
for treatment of tuberculosis and tumours [51]. However, it 
was not always fully believed that drugs could be delivered 
into the circulation.
Then, in the twentieth century, some incidents of 
accidental intoxication were observed, for example 
poisoning by spills of phenol on the skin [61]. This 
phenomenon gave significant insights into the understanding 
of topical and transdermal drug delivery systems. As a 
result, in the 1950s, the first transdermal product in the form 
of an ointment was released to treat angina pectoris, namely 
 Nitrol® (2% nitroglycerin ointment) [51]. Nevertheless, this 
product had limitations, in terms of the application (greasy 
and not reproducible) and the frequency of administration 
(several times a day). Therefore, scientists were incentivised 
to develop ‘measured-dose’ transdermal delivery systems for 
different drugs to reduce the frequency of administration. 
Figure  5 presents a summary of marketed transdermal 
products, based on the available data in previous papers [10, 
51, 62–64].
The first transdermal product containing scopolamine 
(Transderm Scōp®) was marketed in 1979. This product 
was used over 3 days for the treatment of motion sickness 
at sea. The development of Transderm Scōp® had proven 
that transdermal delivery of scopolamine could reduce 
some of the side effects of this drug, when compared to 
oral administration. Consequently, some other APIs 
were formulated into transdermal dosage forms (Fig. 5). 
Following the scopolamine-containing product, Catapress-
TTS®, a clonidine-loaded transdermal patch, was released in 
1984 to treat hypertension. Additional transdermal products 
were also developed and marketed in 1986  (Estraderm®) and 
1990  (Harbitrol® and  Duragesic®). From 1991 until 2004, 
marketed transdermal products were dominated by hormone-
containing contraceptives, such as oestradiol, testosterone, 
ethynyl estradiol, norelgestromine and levonorgestrel. This 
suggested that at the beginning, transdermal products were 
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intended predominantly for the delivery of hydrophobic 
drugs, composed of sterols [65].
From 2005 until 2013, several different types of drugs 
were also formulated into transdermal products, such as 
selegiline  (Emsam®), methylphenidate  (Daytrana®), fentanyl 
 (Ionsys®), diclofenac epolamine  (Flector®), a combination 
of menthol/methylsalycylate  (Salonpas®) and sumatriptan 
 (Zecuity®). Specifically,  Ionsys® and  Zecuity® are examples 
of transdermal product which coupled with iontophoresis for 
enhancing drug absorption from transdermal patch. Recently, 
some transdermal products, such as  Secuado® (asenapine 
for schizophrenia) and  Twirla® (ethinyl estradiol and 
levonorgestrel), were approved by FDA in 2019 and 2020, 
respectively [66]. The development of each transdermal 
product has been predeceased with advances in knowledge 
and understanding of transdermal drug delivery, resulting 
today, in a wide range of transdermal products available to 
patients and clinicians. To ensure progression it is imperative 
to understand a range of technologies that may be useful for 
enhancing drug absorption via the skin.
Technologies for enhancing transdermal 
delivery
Transdermal drug delivery offers some benefits when 
compared to the other administration routes, such as first-
pass metabolism avoidance and ease of self-administration. 
However, due to the dense cellular architecture and the 
hydrophobic characteristics of the SC, not all drugs 
are eligible to be administered using a conventional 
transdermal delivery system. There are several factors that 
may affect drug absorption into the skin.
The first factor affecting skin absorption is the 
physiology of the skin. For instance, the thickness of 
the SC and the amount of lipid in different parts of the 
skin layers, where the transdermal patch is applied, may 
influence the absorption rate of drugs into the skin [8]. The 
quantity of capillary blood vessels in certain skin body 
parts may have an impact on the rate of drug absorption 
into the circulation [67]. Moreover, the presence of 
hair follicles and sweat ducts may also contribute to a 
greater amount of drug permeating into the body, as a 
consequence of transfollicular drug delivery [50]. Body 
temperature affects the vasodilatation of skin capillaries 
and blood flow, resulting in higher rates of absorption [68, 
69]. Furthermore, a higher amount of drug permeation 
may be achieved using an occlusive system to over-hydrate 
the skin [70].
Since the SC is composed of nonpolar lipid and neutral 
keratin proteins, drugs have to possess sufficient solubility 
both in water and oil to be absorbed into the skin [48]. In 
other words, the log partition coefficient (Log P) of the 
drug should be in the range of 1.0–3.0 [71]. Conventional 
transdermal products utilise a passive diffusion of drugs 
upon permeation into the skin. Optimal drug absorption 
Fig. 5  A timeline illustrating the journey of marketed transdermal products from 1981 until 2013
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can be achieved when the molecular size of the drug 
compound is less than 600 Da [43].
In terms of chemical factors, the degree of ionisation of 
the drug has a significant impact on its absorption through 
the skin. For example, unionised compounds may have 
greater drug permeation when compared to the ionisable 
drug, due to the hydrophobic similarity with the SC [48]. 
The melting point of the drug may also affect its permeation 
into the skin. When a drug has a low melting point, its 
solubility in the SC is higher, potentially resulting in a 
greater amount of drug permeating into the skin [72].
Taking each of these factors into consideration, 
researchers have developed numerous methods to enhance 
drug absorption across the skin. Figure  6 presents a 
summary of the strategies employed for the enhancement 
of transdermal drug delivery systems. In this paper, the 
enhancement strategies are classified by pairing the type 
of methods previously reported by Barry [43] and Morrow 
et al. [73] with their generation, categorised by Prausnitz 
and Langer [10].
The first generation of transdermal drug delivery does 
not involve a patch system instead the drug is formulated 
into a conventional liquid spray, gel, cream or other topical 
formulations. These formulations are applied on the skin 
without the involvement of any sophisticated systems or 
platforms [10]. This method utilises passive diffusion to 
achieve absorption into the skin and so the incorporated 
drug must be of low molecular mass (< 600 Da), possessing 
sufficient hydrophobicity and must be effective in low dose 
administration [74]. Some marketed transdermal products, 
as listed in Fig. 5, are examples of this first-generation 
technology, such as  Duragesic® and  Salonpas®. However, 
the delivery of drug using this method is very limited, 
hence some more advanced enhancement methods were 
subsequently developed. Barry [43] and Morrow et al. [73] 
have categorised the approaches for enhancing transdermal 
drug delivery into five methods, as indicated in the purple-
shaded semi-circle in Fig. 6.
Drug‑vehicle interaction
The first method which can be used to improve skin 
absorption is drug-vehicle interaction. Specifically, this 
method is divided into four different techniques: drug/
prodrug selection, ion pairing, eutectic systems and 
chemical potential or thermodynamic methods. These 
techniques were all classified by Prausnitz and Langer [10] 
as second-generation transdermal drug delivery systems. 
A second-generation strategy was aimed at increasing 
skin permeability by modifying the SC and providing an 
additional driving force to across the skin, using methods 
which avoid damages to the deeper skin layer. In this section, 
prodrug and ion pairing methods will be utilised as examples 
of drug/vehicle interactions.
The prodrug approach/technique involves the linking of 
an inactive moiety to a drug, using covalent interactions, so 
that the modified drug (parent drug) is more hydrophobic 
than the active form [73]. This modification is important, 
since the principal SC barrier is composed of nonpolar lipids. 
After administration, the parent drug will be metabolised 
and converted into the active drug [48]. Previous studies 
have shown that utilisation of the prodrug method can 
improve the pharmacological activity of certain drugs. Some 
representative drugs which have been investigated using this 
Fig. 6  Summary of the tech-
nologies utilised for enhancing 
transdermal drug delivery
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approach are stavudine [75], naltrexone [76], bupropion 
[77], morphine [78], indometacin [79], carbamate [80] and 
haloperidol [81].
The next method for increasing drug permeation into the skin 
is ion pairing. This method is suitable for ionised drugs, since 
they are not readily absorbed via the/across the SC [43]. The 
addition of the opposite ion species into the drug formulation 
will result in a neutral paired compound that has a different 
partition coefficient to the SC [73]. Following application of 
the ion-paired molecules, the parent drug will be released and 
then absorbed into the circulation [74]. The release of the drug 
is caused by the partition and diffusion of the ion-pair through 
the SC prior to dissociation in the viable epidermis. Some 
previous studies have reported that the delivery of the following 
drugs was successfully enhanced using the ion pairing method: 
risedronate [82], bisoprolol [83], escitalopram [84], berberine 
[85], zaltoprofen [86] and nicotine [87].
Despite all the advantages documented above, it is worth 
noting that drug-vehicle interaction methods have some 
drawbacks. For instance, a prodrug may result in toxicity 
because of unpredictable metabolism, potentially leading to the 
production of toxic metabolites [88]. Moreover, it is imperative 
to assess the toxicity of the linking agent (inactive moiety) and 
the prodrug itself, due to the possibility of toxic side products 
upon synthesis [89]. Furthermore, the production of a prodrug 
requires complex fabrication considerations/methods and is 
limited only to the generation of small molecules [10]. In 
addition, the delivery of both ion-pairs and prodrugs are still 
reliant on passive diffusion techniques and, therefore, the SC 
still remains a challenge when considering the transdermal 
delivery of drugs in these forms.
Vesicles and analogues
The second approach for enhancing transdermal drug 
delivery is the utilisation of vesicles and their analogues. In 
2008, this strategy was categorised as the second generation 
of transdermal products [10]. Nanovesicles are defined as 
nano-size spherical bilayer vesicles made up of lipids or 
other analogues, such as surfactant [90]. Some nanovesicles 
used to facilitate transdermal delivery include liposomes, 
ethosomes, transfersomes, niosomes and phytosomes. These 
nanovesicles are classified based upon the main component 
used in the formulation. Different types of nanovesicles are 
described and summarised in Fig. 7.
Liposomes were the first artificial vesicles developed by 
Bangham and Horne in 1964, composed of phospholipid 
and cholesterol [91]. Liposomes may be composed of one 
or more bilayer concentric membranes, namely unilamellar 
vesicles (ULVs) or multilamellar vesicles (MLVs), 
respectively [92]. Phospholipids, as the main component of 
liposomes, are amphiphilic molecules, composed of a polar 
head and a nonpolar tail [93]. Therefore, liposomes can be 
used for encapsulation of both hydrophilic and hydrophobic 
drugs [94]. When the drug is hydrophilic, it will be 
entrapped in the core (interior) of the liposome vesicles, 
as depicted in Fig. 7. Conversely, a hydrophobic molecule 
will be encapsulated in the middle of the lipid bilayer that 
is constructed of nonpolar tails of the phospholipid [95]. 
Liposomes will be absorbed onto the skin and fuse with 
the lipid bilayer of SC, which resulting in the disruption 
of the outer layer integrity. Therefore, the lipids act as skin 
penetration enhancers that facilitate drug permeation into 
skin [73]. Liposomes have been used for the delivery of 
various different kinds of drugs, such as diclofenac [96], 
baicalein [97], amphotericin B [98], ketoprofen [99], vitamin 
C [100] and azithromycin [101].
The second type of nanovesicle utilised for transdermal 
drug delivery systems is the ethosomes. Ethosomes 
were first developed by Touitou et  al. [102]. The main 
composition of ethosomes is phospholipid and alcohol 
(20–45%), such as ethanol or isopropyl alcohol [102]. 
Fig. 7  A schematic illustration 
of a variety of different nan-
ovesicles developed for use in 
transdermal delivery systems
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The use of ethanol in ethosomes was aimed at improving 
the flexibility of conventional liposomes and functions 
as an enhancer upon permeation of the drug into the skin 
[103, 104]. Ethosomes were deemed to possess better 
biocompatibility and higher drug permeabilities, compared 
to conventional liposomes [105]. Some representative drugs 
which have been successfully delivered using ethosomes 
include the following: apigenin [106], valsartan [107], 
econazole nitrate [108], quercetin [109], indometacin [110], 
curcumin [111], green tea extract [112] and mitoxantrone 
[113]. A modification of ethosomes, namely transethosome, 
was introduced by Song et al. [114] who combined the 
use of phospholipids, with high amounts of ethanol and 
surfactant, acting as permeation enhancers, for delivery 
of voriconazole. This technology has been investigated 
for the delivery of fisetin [115], piroxicam [116], paeonol 
[117], epigallocatechin gallate-containing extract [118] and 
agomelatine [119].
Transfersomes are ultra-deformable liposomes that 
were invented by Cevc and Blume and were composed of 
phospholipid and edge activator (single chain surfactant) 
[120]. The edge activator is a component that destabilises the 
lipid bilayer and makes transfersomes much more flexible 
and deformable, compared to a conventional liposomes 
[121]. This deformable structure allows the transfersomes 
to penetrate into the deeper skin layers, using elastic 
transport [122]. Additionally, skin hydration and osmotic 
mechanisms are also involved in the penetration processes 
of transfersomes [123]. Similar to liposomes, transfersomes 
can encapsulate both hydrophobic and hydrophilic drugs 
(Fig. 7). Recent studies have shown that cilnidipine [124], 
diflunisal [125], sinomenine [126], green tea extract [127], 
pentoxifylline [128], raloxifene [129] and minoxidil [130] 
were all successfully formulated and delivered transdermally 
using transfersomes.
Surfactant-based nanovesicles called niosomes can also 
be used for improving transdermal delivery. Niosomes are 
mostly prepared with single chain nonionic surfactants 
using a hydration method to form a bilayer structure 
[131]. In terms of composition, niosomes can also contain 
cholesterol to form a rigid structure [132]. Two kinds of 
nonionic surfactants which have been employed in the 
manufacturing of niosomes are Tween and Span [133]. 
Similar to phospholipid, nonionic surfactants also consist 
of hydrophilic heads and hydrophobic alkyl chains (tails). 
Hence, niosomes can be used for incorporating both polar 
and nonpolar compounds [134]. Niosome systems have been 
reported to enhance the transdermal delivery of salidroside 
[135], sulfadiazine [136], capsaicin [137], resveratrol [138], 
atenolol [139] and sumatriptan [140].
The final type of nanovesicles developed for enhancing 
drug absorption via the skin is the phytosomes which are 
lipid-based nanovesicles designed to facilitate delivery 
of hydrophilic phytoconstituents [141]. Phytosomes are 
also known as phyto-phospholipid complexes due to the 
complexation of active constituents from plant extracts and 
phospholipids by covalent interactions [142]. Thus, the 
entrapment of drug molecules in phytosomes is different 
from liposomes and other analogues, such as ethosomes or 
transfersomes [143]. In phytosomes, the hydrophilic drug 
is entrapped in the polar head of the phospholipid as a 
complex, while in liposomes the drug is encapsulated in the 
interior of the vesicles, as presented in Fig. 7. Phytosomes 
have been utilised for increasing bioavailability of natural 
compounds, such as curcumin [144], sinigrin [145], 
Moringa oleifera extract [146], Centella asiatica [147] and 
18ß-glycyrrhetinic acid [148].
Although there are numerous prospective uses of nan-
ovesicles in facilitated transdermal drug delivery, there are 
also some limitations associated with this technology, such 
as instability of manufactured products, batch reproducibil-
ity, large-scale production, low drug loading and maintain-
ing the particle size during preparation [149]. Furthermore, 
high cost instrumentation and methods are required for 
manufacturing of these nanovesicle-based technologies [90]. 
Moreover, it has been previously reported that, liposomal 
technology can hinder the penetration of small molecules 
through the skin [150]. Therefore, other novel enhancement 
strategies have also been developed to facilitate transdermal 
delivery of drugs.
Stratum corneum modification
Modification of the properties of the SC may lead to improved 
permeability of drugs into the skin. Morrow et  al. [73] 
categorised skin hydration and the use of chemical enhancers 
as methods for modifying the SC. Based on this classification, 
these methods are included in the second generation of 
transdermal delivery (Fig. 6), or in other words, modifying 
SC without causing any skin damage [10]. Skin hydration is a 
process to increase skin humidity and water content, so that the 
drug can more easily permeate into the SC. Several methods 
which have been employed for maintaining water content, 
such as the use of occlusive dressing and patches; preventing 
water loss by adding lipid excipients to the formulation and 
increasing skin humidity using humectants [43]. Tan et al. 
[151] investigated the effects of occlusive wet hydration 
patches on the structure of the SC. They found that, after 6 h 
of hydration, separation of the lipid bilayer of the SC occurred, 
thus altering the permeability of porcine skin significantly. 
Moreover, Paudel et al. [152] has previously reported that skin 
hydration, using an occlusive system, may cause a reduction 
in diffusional resistance of the skin to xenobiotics. In addition, 
the use of such systems may also positively affect the flux 
of numerous drugs by increasing the amount permeated and 
ultimately affecting the absorption rate into the skin [153].
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Modification of the SC can also be achieved using 
chemical permeation enhancers. Chemical enhancers 
function by disrupting the lipid bilayer of the SC, interacting 
with proteins or modifying the partition coefficient of the 
drug [74]. These compounds have been widely used in many 
transdermal products to increase drug permeation. It is 
necessary, however, to consider the safety of such chemicals. 
Thus, not all types of chemicals can be used as transdermal 
enhancers as there are specific requirements for their use 
in pharmaceutical products. These chemicals must be inert, 
nontoxic, nonallergenic, nonirritant, preferably elicit rapid 
effects, be aesthetically accepted and crucially skin barrier 
function must recover quickly after the chemicals have been 
removed [154, 155]. Figure 8 summarises the information 
available from published sources, highlighting the chemical 
enhancer groups used, to date, in transdermal drug delivery 
systems [10, 43, 73, 74, 155].
Looking at one example from the sulphoxides, dimethyl 
sulphoxide (DMSO) has been used to enhance drug 
absorption by interacting with lipid domains of the SC 
[73]. DMSO may also denature the protein components 
and change the intercellular keratin conformation of the SC 
[155]. Recently, DMSO has been investigated for enhancing 
transdermal delivery of hydrophilic drugs by altering the 
diffusivity in the SC corneocytes [156]. Several drugs, 
including fenoterol hydrobromide [157], hydrocortisone 
[158], testosterone [159] and naloxone [160] have been 
successfully delivered transdermally using DMSO as a 
permeation enhancer.
A second group of chemical enhancers known as 
azone (1-dodecylazacycloheptan-2-one) can be used as 
a permeation enhancer, interacting with lipids of the SC 
and disrupting the lipid packing arrangement of the bilayer 
[155]. Azone has been utilised for delivery of levamisole 
hydrochloride [161], ketoprofen [162], dimethyl fumarate 
[163] and 5-fluorouracil [164]. Even though azone is 
effective at low concentration as an enhancer, this compound 
has been still investigated its metabolism in the body and, 
therefore, has not ever been used in commercial products 
[155]. Other synthetic chemical permeation enhancers are 
from the pyrrolidone group, including n-methyl pyrrolidone 
and 2-pyrrolidone. These chemicals can interact with 
the keratinised region of the SC and alter the solubility 
properties of the SC [73]. N-methyl pyrrolidone has been 
Fig. 8  Classification and mech-
anisms of action of a variety 
of different chemical enhancer 
groups used in the facilitated 
delivery of drugs transdermally 
(SC: Stratum corneum)
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investigated for delivery of ketoprofen [162], lidocaine 
hydrochloride [165], bupranolol [166] and 5-hydroxymethyl 
tolterodine [167] via transdermal route.
Fatty acids can also act as chemical permeation 
enhancers. As previously explained, the SC is composed 
of lipids and possesses hydrophobic characteristics. 
Therefore, the usage of fatty acids, such as oleic acid and 
lauric acid, will increase drug permeation through the skin 
due to the similar hydrophobicity, compared to the lipids 
of the SC. These fatty acids will interact and modify lipid 
domains of the SC by disrupting lipid bilayer packing [153]. 
Flurbiprofen [168], propranolol [169], theophylline [170] 
and donepezil [171] are examples of drugs, the transdermal 
delivery of which was enhanced using fatty acids.
Alcohols, such as ethanol, propylene glycol and isopropyl 
alcohol, also act as skin permeation enhancers. These 
solvents can increase drug solubility in the SC by altering 
the solvent properties of the SC, resulting in improvement 
of drug partitioning [43]. Moreover, a gradient concentration 
mechanism is also involved in this enhancement, as alcohols 
evaporate quickly after application [155]. Additionally, 
ethanol may also cause slight disruption of the intercellular 
lipid geometry of the SC [73]. Alcohol has been used for 
improving transdermal permeation of several drugs, such 
as thyrotropin releasing hormone [172], nortriptyline 
hydrochloride [173], thymoquinone [174] and lidocaine [175].
Surfactants are amphiphilic molecules which have both 
polar and nonpolar functional groups [155]. Surfactants 
can solubilise the lipids of the SC, disrupting the lipid 
and protein domains and penetrate through the lipid 
bilayer [176]. Surfactants which have been widely used for 
enhancing transdermal absorption of drugs are sodium lauryl 
sulfate (SLS) and polysorbate (Tween). SLS was studied as a 
means of increasing transdermal delivery of lorazepam [177] 
and foscarnet [178], while polysorbate has been reported as 
an enhancer of the transdermal delivery of L-ascorbic acid 
[179] and dimethyl fumarate [163]. Similar to the surfactant 
group, urea is also employed for improving skin absorption 
of drugs by disrupting SC lipids, increasing water content 
of the skin and initiating keratolytic activity [153]. Urea 
has been investigated as an enhancer of transdermal drug 
delivery in some formulations containing indometacin [180], 
venlafaxine hydrochloride [181] and metronidazole [182].
The last group of chemical enhancers that will be 
explained in this section is the terpenes group. Terpenes are 
volatile compounds (mostly extracted from natural products) 
which are constructed of carbon, hydrogen and oxygen atoms 
[183]. Monoterpenes  (C10) and sesquiterpenes  (C15) are 
two kinds of terpenes with high percutaneous enhancement 
activities. Limonene, cineol, menthol and carvacrol are 
included to the monoterpenes class, while bisabolol, farnesol 
and nerolidol are in the sesquiterpenes class [183]. The 
mechanism of action of terpenes as permeation enhancers 
is by modifying the solvent nature of the SC and improving 
drug partitioning into the SC [155]. Moreover, terpenes can 
also disrupt the SC lipid bilayers and modify diffusivity 
of drug delivered [73]. Chen et al. [183] have summarised 
additional modes of action of terpenes, such as extracting 
part of the SC lipids, denaturation of keratin and disordering 
the lipid arrangement in the SC. Terpenes have been 
investigated in in vitro studies as permeation enhancers for 
transdermal delivery of propranolol [184], pizotifen [185], 
zidovudine [186], dimethyl fumarate [163] and imipramine 
hydrochloride [187].
In spite of these enhancement methods showing 
significant promise, there are some disadvantages associated 
with the use of chemical enhancers. For example, some of 
the chemicals are toxic and may cause skin irritation when 
used at high concentrations, such as DMSO [155]. Moreover, 
chemical enhancement is a concentration-dependent method. 
Hence, it may prove ineffective at particular concentrations 
[73]. Additionally, the effective concentration for each 
type of chemical enhancer is different for each drug [188]. 
As such, a combination approach, using different types of 
chemical enhancers has been employed to investigate the 
different ways of increasing drug permeation across the skin 
(Fig. 6). This combination has been categorised as the third 
generation of transdermal enhancement methods [10].
Energy‑driven methods
Energy-driven or electrically assisted methods of 
transdermal delivery use electrical devices for enhancing 
absorption of drugs into the skin. Based on Prausnitz and 
Langer’s classification [10] and Morrow et al. [73], the 
energy-driven methods are divided into two generations, 
as previously displayed in Fig. 6. The second generation 
of electrically assisted methods are iontophoresis and 
noncavitational ultrasound, whereas the third generation 
are electroporation, sonophoresis and thermal ablation. 
Prausnitz and Langer [10] classified the iontophoresis as 
the second generation, since this technology does not give a 
large impact on the SC, such as microchannel creation or SC 
removal, as found in electroporation and microscissioning, 
respectively. In contrast, the third generation of enhancement 
technology requires stronger disruption of the SC, because 
the main target of these methods is to disrupt or remove 
the SC, without causing damage to the deeper skin tissue 
[10]. In this review article, the second-generation energy-
driven methodology, iontophoresis, and the third-generation 
methods of sonophoresis and electroporation will be 
described as examples of these approaches.
Iontophoresis is defined as a method for increasing 
permeation of drugs into the skin using small electrical 
currents [189]. The electrical current applied in iontophoresis 
varies from 0.5 to 20  mA [190]. The principle of this 
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system is based on the different charges of the electrodes 
used, namely the anode and cathode. Anionic drugs are 
placed underneath a cathode, and the cationic or neutral 
drugs are placed ions under the anode. Upon application 
of low electricity current at low voltage, ions permeate 
into the skin [73]. In the skin, the anions are mobilised 
to the anode by a repel pulse from the cathode, and vice 
versa for the cation, as illustrated in Fig. 9. Iontophoresis 
is mostly used for increasing skin absorption of ionisable 
drugs [191]. However, this technology can also be used for 
delivery of weak charged or neutral molecules [10] through 
electroosmosis [73]. There are some factors that may affect 
drug delivery via iontophoresis, such as formulation, 
physiology of the application site, physicochemical 
characteristics of the drug delivered, duration of application 
and the instrument parameters [191]. Iontophoresis has been 
investigated for delivery of various kinds of drugs, including 
nonsteroidal anti-inflammatory drugs (ibuprofen, aspirin and 
indometacin) [192], almotriptan [193], granisetron [194], 
sodium nonivamide acetate [195], donepezil [196] and 
insulin [197]. Despite the wide utilisation of iontophoresis, 
this system has some associated limitations, such as the 
possibility of skin irritation and current-induced damage 
to the skin, the requirements of instrument setup, their 
complexity of use for patients, the drug ions may not easily 
permeate into the skin and the drug delivered may be limited 
to the small molecular weight (MW) drugs (< 10,000 Da) 
[198]. Moreover, the electrodes tend to corrode upon storage 
due to the aqueous gel nature of the adhesive [199]. The 
absence of any commercial iontophoresis devices on the 
market for drug delivery may be caused by the difficulty to 
predict the complex bioavailability of drugs delivered from 
iontophoretic product [199]. Furthermore, this delivery 
platform is more expensive compared to the other types of 
marketed transdermal products [199].
The next method for enhancing transdermal absorption 
is sonophoresis, also known as phonophoresis. This 
system uses ultrasound at frequencies of 20 kHz–16 MHz 
for modifying lipid bilayer arrangement of the SC [200]. 
There are two possible enhancement mechanisms of 
action via sonophoresis, namely, thermal effects and 
cavitation (including stable and inertial cavitation) [201]. 
By applying ultrasound, the skin temperature increases, 
resulting in higher drug diffusivity into the skin [202]. The 
cavitation mechanism refers to the formation of cavities and 
bubbles in the SC. When ultrasound is applied, it causes 
a continuous oscillation and a stable cavitation, inducing 
bubbles around the application area [201]. This mechanism 
Fig. 9  Schematic diagram illustrating the delivery mechanism of cati-
onic drugs using iontophoresis. The black arrows in the skin describe 
the flow of cationic drug moves from drug solution to the cathode. 
Conversely, the white arrows show the movement of anions from 
buffer solution under the cathode to the anode
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is termed stable cavitation. Inertial cavitation is defined as 
the creation of bubbles inside the liquid medium in a single 
or multiple cycles upon the application of ultrasound [201]. 
In sonophoresis, the drug solution is placed under the probe 
equipment and then a predetermined ultrasound frequency 
is applied onto the drug solution and skin [203]. Upon 
ultrasound exposure, the cavities and bubbles are created, 
causing the disruption of lipid bilayer packing in the SC 
(particularly in the interface of keratinocytes and lipids of 
SC) [204]. Figure 10 depicts the mechanism of drug release 
using sonophoresis.
Drug delivery systems using sonophoresis are influenced 
by a number of factors, such as the frequency, intensity 
and mode of ultrasound [205]. Several other parameters 
that may affect the success of sonophoresis are application 
time of the ultrasound, coupling medium, and distance of 
ultrasonic probe from the skin [206, 207]. Sonophoresis is 
beneficial for the delivery of a variety of different kinds of 
drugs. For instance, it has been reported that sonophoresis 
was successfully employed as a transdermal enhancement 
method in the delivery of ketoprofen [207], fluocinolone 
acetonide [208], vancomycin [209], gemcitabine 
hydrochloride [210] and proteins (insulin, interferon y, 
and erythropoietin) [211]. Many different classes of drugs 
have been successfully delivered using this approach. This 
indicates that sonophoresis can be used to facilitate the 
delivery of hydrophobic and hydrophilic drugs but also 
small molecules and macromolecules. There are some 
disadvantages associated with sonophoresis, however, such 
as the time-consuming nature of the technique, requirement 
for sophisticated instrumentation and skin must be in a 
healthy condition during application [212].
The final example of an energy-assisted enhancement 
method is electroporation. Electroporation is a technique 
utilised to create micropores in the skin by applying high 
voltage (10–1000 V) over a very short time period (less 
than a few hundred milliseconds) [73]. The principle of 
electroporation involves exposing a drug solution, which 
has been placed on the skin, to pulse waves [213]. This 
pulse wave will create aqueous pores in the lipid bilayer 
of the SC and allow drug penetration into the deeper 
skin layers via the pores created, as detailed in Fig. 11. 
Therefore, this method holds the potential to deliver 
macromolecules across the skin as the pores are created 
in the SC itself.
Drug delivery using electroporation is affected 
by several factors, for example the physicochemical 
properties of the drug, voltage used, length of pulse 
and number of pulses [213]. Electroporation has been 
employed to enhance the in vitro transdermal absorption of 
various drugs, including tetracaine [214], alniditan [215], 
insulin [216], fentanyl [217], timolol [218] and calcein 
[219]. An example of transdermal in vivo delivery using 
electroporation was reported by Blagus et al. [220] who 
investigated the permeation of dextran, doxorubicin and 
fentanyl in a rat model. Nevertheless, electroporation 
Fig. 10  A schematic illustration of sonophoresis-assisted transdermal drug delivery. Following the application of ultrasound, the drug molecules 
will be delivered into dermis
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may suffer from some limitations, such as the need for 
sophisticated and high-cost instrumentation, complicated 
and time consuming means of application, the necessity 
for expert personnel, low throughput of the drug delivered 
due to the limited area of aqueous pores created, the 
possibility of cell damage because of high voltages utilised 
[212, 221]
Stratum corneum bypassed
Innovative enhancement technologies aimed at bypassing 
the SC have also undergone considerable research and 
development. In this section, the use of bypass methods 
will be explored, facilitating transdermal delivery of a 
wide variety of drugs. A skin bypassed technique which 
is included to the second generation of enhancement 
technology is transfollicular delivery (Fig. 6). Transfollicular 
delivery refers to drug delivery via hair follicles as the 
principal absorption route [222]. As previously explained, 
however, this route is limited by the area of hair follicles on 
the skin, which is only ~ 0.1% of the skin surface area [43].
Tape-stripping, microscissioning and microneedles are 
examples of third generation skin bypassing methods. Tape-
stripping is a technique to remove the superficial SC layers 
by applying adhesive tape on the skin surface for several 
times [73]. By removing the successive layers of the SC 
(Fig. 12a), drug permeation into skin may be improved. 
Despite the simple and cheap method used, such system 
has a low reproducibility and is inconvenient for regular 
applications [73]. A more advanced technique for disrupting 
SC of the skin is by using microscissioning, which was firstly 
reported by Herndon et al. [223]. In this technique, the SC is 
removed gradually using aluminium oxide particles which 
are mobilised in an accelerated velocity. The accelerated 
particles will cut the SC and create microconduits in the 
skin (Fig. 12b). Nevertheless, this technique shows some 
drawbacks, such as time-consuming preparation, particles 
deposition in the skin and the possibility of infections 
following the application [73]. The last SC bypassed 
method employed for improving transdermal drug delivery 
is microneedles.
Microneedles
Microneedles (MNs) are micron-sized needles, on a solid 
support, with needle heights ranging between 25 and 
2000  µm. These needles can pierce the SC and create 
microconduits, following insertion into the skin [49, 224]. 
The first concept of MN was introduced by Gerstel and Place 
[225] in their patent, entitled ‘Drug Delivery Device’. This 
outlined the basic design of MN that continues to undergo 
development today. This finding was then followed by 
Gross and Kelly [226] who published a patent about the 
Fig. 11  Schematic diagram illustrating transdermal drug delivery using the energy-driven electroporation method. Electroporation helps the 
drug to permeate into the dermis layer
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first hollow needle connected to an expansible-contractible 
drug chamber for intradermal drug delivery system. In 1997, 
another discovery was reported by Jang, who proposed a 
skin perforating device which was aimed at transdermal 
delivery [227]. Henry et al. [228] manufactured solid MN 
(made of silicon) for transdermal delivery of calcein as a 
scientific demonstration of MN.
Following this invention, other types of MNs were 
developed. Zahn et  al. [229] invented hollow MN and 
this technology utilises the ability of MN to penetrate 
the skin, following which a drug solution is injected 
through the hollow needles into the skin [224]. Coated 
MNs were developed by Cormier et al. [230] for delivery 
of desmopressin. In this work, the needle tips of the MN 
were coated with desmopressin solution and delivery was 
evaluated in an animal model. A further exploration of MN 
was investigated by Park et al. in 2006. They mixed drug 
(calcein or bovine serum albumin) with PLGA as the MN 
material [231]. The drug-containing needles of the MN 
dissolved upon insertion into the skin, hence this platform 
was named, dissolving MN. The most recent type of MN was 
invented by Donnelly et al. [232], namely hydrogel-forming 
MN. Even though the paper was published in 2012, the 
patent was filed in September 2007 [233]. This MN is made 
of hydrogel-forming polymer that can absorb interstitial fluid 
and swell in the skin after insertion [232]. This technology is 
completely different from dissolving MN as the drug is not 
mixed with the MN polymer. A drug-containing reservoir 
is instead integrated with the MN prior to application. 
Figure 13 depicts a brief timeline of MN evolution over 
time, and Fig. 14 is schematic representations of the drug 
delivery approaches of each different MN.
MNs have been widely used for enhancing transdermal 
delivery of numerous kinds of drugs. MNs are able to 
penetrate the SC of the skin and reach the dermis without 
breaching nerve endings and blood vessels in the dermal 
layer [49]. Consequently, upon administration, MNs are 
less painful and more comfortable compared to hypodermic 
Fig. 12  Diagram illustrating the process of (a) skin tape-stripping and (b) microscissioning
Fig. 13  A timeline summarising 
fundamental findings of MNs 
since the first conceptualisation 
in 1976 until the invention of 
the last MN type in 2012
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injection. Furthermore, dissolving and hydrogel-forming 
MNs can avoid the need for sharps waste disposal and does 
not contribute to transmission of blood borne diseases the way 
traditional needle and syringe devices can [234]. Moreover, 
this technology offers considerable benefits over other 
transdermal enhancement methods explained in the previous 
section. For instance, since the SC is by-passed, delivery of 
macromolecules is more feasible using MN. In addition, the 
skin can quickly recover after the MN is removed [235]; 
thus, this may prevent irritation or secondary infections at 
the application site [236]. In terms of materials, MNs are 
generally manufactured using biocompatible substances 
or biodegradable polymers [224]. It is important to ensure 
that MN materials are safe and do not induce inflammation 
response after the insertion [237]. For routine use, such as 
in insulin therapy, MNs are possible for self-administration 
and easy to apply on the skin by patients [238]. The benefits 
documented above have shown that MNs are designated as a 
promising strategy to improve drug permeation into the skin. 
To have a better understanding of MN delivery, each type of 
MN will be explained in the subsequent sections.
Solid microneedles
The first MN developed for enhancing transdermal drug 
delivery was the solid MN. Solid MNs use the microconduits 
created in the skin by the MN as drug absorption channels 
[224]. Following insertion, the MNs are removed and 
a transdermal patch is applied onto the microconduits 
(Fig. 14a). Then, the drugs are released via passive diffusion 
from the drug formulation and permeate through the 
microconduits into the skin [224]. As previously explained, 
solid MNs were primarily made of silicon for delivery of 
calcein [228]. After this invention, solid MNs were then 
manufactured using different types of materials, including 
metal, ceramic and polymers [49]. For example, a tungsten-
based solid MN has been manufactured by Ma et al. [239], 
and Tsuchiya et al. [240] has reported a metal-based solid 
MN fabricated from titanium. Another metal which has been 
used for manufacturing solid MN is stainless steel. Verbaan 
et  al. [241] have used stainless steel-30G hypodermic 
needles as MN material by cutting and attaching these 
needles to a poly(etheretherketone) mould. With respect to 
ceramic-based MN, Bystrova and Luttge [242] manufactured 
this type of MN by casting alumina slurry into micromoulds. 
Additionally, different types of ceramic (calcium sulfate 
dihydrate) were also employed as materials for manufacture 
of solid MN, as previously described by Cai et al. [243]. A 
solid polymer MN made of poly(lactic acid) was reported 
by Li et al. [244] for delivery of insulin in a diabetic model 
rat. Figure 15 displays some solid MNs fabricated using a 
variety of different materials: (a) silicon [228], (b) tungsten 
[239], (c) calcium sulfate dihydrate [243] and (d) polylactic 
acid [244].
Fig. 14  Drug delivery approach via different type of MN: (a) solid, (b) coated, (c) hollow, (d) dissolving and (e) hydrogel-forming MNs
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Previous studies have shown that solid MN can be used 
for delivering a wide variety of drugs. A combination of 
nanoemulsion and stainless-steel solid MN has recently 
been investigated for improving transdermal delivery of 
aceclofenac [245]. Moreover, it was reported by Abiandu 
et al. [246] that the use of solid MN (rollers) can significantly 
increase in vitro flux of potassium chloride when compared 
to the passive diffusion group. With regards to delivery 
of macromolecules, Martanto et al. [247] have used solid 
MN for increasing transdermal delivery of insulin. The 
transdermal delivery of some other drugs has been enhanced 
using solid MN, including bovine serum albumin (BSA) 
[248], amantadine hydrochloride [249], levodopa [250] and 
ovalbumin [251]. Despite the wide variety of drugs that can 
be delivered using this approach, solid MN may have some 
practical issues associated with them, due to the requirement 
for a two-step application process [224]. Moreover, some 
materials are brittle, nonbiocompatible and may induce 
inflammatory response in the patient [49].
Coated microneedles
Coated MNs are fabricated by coating the needle tips of the 
MN with drug formulation [224], either a drug solution or 
dispersion layer. To prepare the coating, drugs are mixed 
with thickening agents and surfactants in order to ensure the 
drugs adhere onto the MN tips prior to insertion into the skin 
[252]. In terms of materials, the MN can be prepared from 
metals or polymer, since the basic technology requires the 
production of a solid MN [252, 253]. Following insertion 
of the MN into the skin, the drug coating is deposited and 
dissolves upon contact with interstitial fluid (Fig. 14b).
Coated MNs have been investigated for delivery of 
macromolecules since their first invention. The first 
utilisation of coated MN, as previously explained, 
was reported by Cormier et  al. [230] for delivery of 
desmopressin. Subsequently, this type of MN has been 
Fig. 15  Representative images 
of solid MNs which were made 
using (a) silicon (reproduced 
with permission from [228]  
Copyright 1998, Elsevier), 
(b) tungsten (reprinted with 
permission from [239] Copy-
right 2016, American Vacuum 
Society), (c) calcium sulfate 
dihydrate (reprinted with per-
mission from [243] Copyright 
© 2014, Royal Society of 
Chemistry) and (d) polylactic 
acid (reprinted with permission 
from [244] Copyright © 2017, 
Royal Society of Chemistry)
Fig. 16  Coated MN with different drug coatings: (a) Desmopressin 
(reproduced with permission from [230]  Copyright 2004, Elsevier). 
(b) DNA (reprinted with permission from [255] Copyright © 2010, 
American Chemical Society)
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used for enhancing the delivery of other macromolecules, 
such as insulin [254], deoxyribonucleic acid (DNA) [255], 
exendin-4 [256], botulinum toxin-A [257] and peptide-A 
[258]. Furthermore, the use of coated MN has also been 
reported for delivery of lidocaine [259] and riboflavin [260]. 
The use of coated MN allows a one-step application process 
which is easier than that required for solid MN. However, the 
main drawback of using coated MN is the limited amount of 
drug that can be delivered, due to the constraints/restrictions 
of the coating surface [224]. Figure 16 shows a series of 
representatives of coated MN with various kinds of needle 
shapes and drug coating: (a) desmopressin [230] and (b) 
DNA [255].
Hollow microneedles
Hollow MNs are designated to deliver drug continuously 
via needles bores into the skin. In hollow MN, the drug 
formulation (solution or dispersion) is loaded in the interior 
of the MN, then the drug is injected and transferred into the 
skin after insertion of the MN (Fig. 14c). Hollow MNs allow 
greater amounts of drug loading, when compared to solid 
and coated MN. Similar to solid MN, hollow MN can be 
manufactured using metals, silicon, glass or polymers [261]. 
Shikida et al. [262] developed hollow MN using nickel. 
Silicon- and glass-based hollow MNs have been previously 
described by Jurčíček et al. [263] and McAllister et al. [248], 
respectively. With regard to hollow polymer MN, some 
materials which have been used for manufacturing this type 
of MN are poly(oxymethylene) [264], poly(imide) [265] and 
poly(methyl meta acrylic) [266]. Insulin has been delivered 
transdermally using hollow MN [267]. However, the use of 
hollow MN is not limited to transdermal delivery purposes. 
For instance, Niu et al. [268] have investigated intradermal 
delivery of vaccine nanoparticles using hollow MN in a rat 
model. The major disadvantage of using hollow MN is the 
possibility of blockage after the needles are inserted due to 
the open needle bores. Figure 17 depicts examples of hollow 
MNs which are fabricated using different materials: (a) glass 
[267] and (b) silicon [269].
Dissolving microneedles
Dissolving MNs represent a distinct section of MN 
technology. Following insertion, the needles dissolve in 
the skin and the drugs are released gradually from the MN 
matrix (Fig. 14d). For fabricating dissolving MN, the drugs 
are mixed with soluble and biocompatible polymers [224]. 
Thus, drug release rate is mainly influenced by the polymer 
composition and MN matrices [224]. Dissolving MNs have 
been manufactured using numerous different polymers, such 
as poly(lactide-co-glycolide) [231], carboxy methyl cellulose 
[270], poly(vinyl alcohol) [271], poly(vinyl pyrrolidone) 
[272], hyaluronic acid [273], pullulan [274] and copolymers 
of methyl vinyl ether and maleic acid [275].
Many different drugs have been successfully delivered 
transdermally using dissolving MN. For instance, this 
technology has been investigated both in in  vitro and 
in vivo studies for delivery of vancomycin hydrochloride 
[276], vitamin B12 [277], rilpivirine [271], dutasteride 
[270], bevacizumab [278], albendazole [279], insulin [261], 
ovalbumin [273] and sumatriptan [280]. Figure 18 shows 
some examples of dissolving MN which fabricated from 
different polymers: (a) poly(vinylpyrrolidone) [281], (b) 
poly (vinylpyrrolidone) [277] and (c) pullulan [274].
These studies have shown that dissolving MN can be used 
for delivering both small and large MW drugs. Moreover, 
the drugs documented above are also varied in terms of 
polarity. Although dissolving MNs are more suitable for 
Fig. 17  Hollow MNs made of (a) glass (reproduced with permission 
from [267]  Copyright 2006, Elsevier) and (b) silicon [269] (this is an 
open access article)
Fig. 18  Micrographs of dis-
solving MN fabricated from 
(a) poly(vinylpyrrolidone) 
(reproduced with permission 
from [281]  Copyright 2008, 
John Wiley and Sons), (b) 
poly(vinylpyrrolidone) (repro-
duced with permission from 
[277] Copyright 2019, Elsevier) 
and c pullulan [274] (this is an 
open access article)
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water soluble drugs, this type of MN has also been explored 
for delivery of hydrophobic drugs in particulate systems, 
such as solid lipid nanoparticles [279] and microparticles 
[282]. However, dissolving MN also have some inherent 
drawbacks, such as the deposition of polymers in the skin, 
limited amounts of drug that can be formulated in the 
needles and subsequently delivered into the skin [224]. In a 
repeat application of dissolving MN, the deposition of high 
MW synthetic polymers in the skin may induce erythema 
or hepatic/lymphatic accumulation, as previously described 
[274, 283].
Hydrogel‑forming microneedles
The most recent type of MN developed is hydrogel-forming 
MNs. Instead of mixing the drugs with polymers, this 
technology utilises a drug-containing reservoir which is then 
integrated with blank MN upon application. The difference 
here is that, after insertion into the skin, the MN can absorb 
a considerable amount of interstitial fluid and swell in the 
skin. Then, the drug-containing reservoir dissolves and 
drug molecules diffuse through the swollen MN conduits 
into the skin (Fig. 14e). The first hydrogel-forming MN was 
manufactured from aqueous blends containing poly(methyl 
vinyl ether-co-maleic anhydride) and poly(ethylene glycol) 
[232]. Drug-loaded films were integrated with hydrogel-
forming MN for delivery of six different drugs, including 
BSA, insulin, caffeine, theophylline and metronidazole. This 
invention has become a pioneer of some other studies that 
have coupled hydrogel-forming MN with different kinds of 
reservoir, such as lyophilised wafers [284–286], co-solvents 
[287] and compressed tablets [276]. Some other materials, 
such as poly(methyl vinyl ether-co-maleic acid)-crosslinked 
pectin [288], poly(vinyl alcohol) crosslinked-gelatin [289] 
and 2-hydroxyethyl methacrylate (HEMA)-crosslinked 
ethylene glycol dimethacrylate (EGDMA) [290], have also 
been investigated for fabricating hydrogel-forming MN. 
Figure 19 depicts some representative images of hydrogel-
forming MN made of different polymers: (a) poly(methyl 
vinyl ether-co-maleic acid) crosslinked with polyethylene 
glycol [291], (b) poly(vinyl alcohol) crosslinked-gelatin 
[289], (c) HEMA-crosslinked EGDMA [290] and (d) a 
swollen hydrogel-forming MN post in vitro permeation 
study [291].
Hydrogel-forming MNs have been used for enhancing 
transdermal absorption of various active compounds. 
Donnelly et  al. [284] have previously investigated the 
use of hydrogel-forming MN and lyophilised wafers for 
transdermal delivery of small and large molecules, namely 
ibuprofen sodium and ovalbumin, respectively. Similarly, 
the capability of hydrogel-forming MN in enhancing skin 
absorption of small molecules has also been reported by 
Kearney et  al. [292]. In this study, hydrogel-forming 
MNs were combined with film reservoirs for delivery 
of donepezil in a rat model. Subsequently, in 2018, 
lyophilised wafers integrated with hydrogel-forming MN 
were successfully employed to improve bioavailability of 
metformin hydrochloride in a rat model [285]. In terms of 
protein samples, Courtenay et al. [278, 286] have reported 
the potential use of hydrogel-forming MN for delivery of 
Fig. 19  Hydrogel-forming 
MN made of (a) poly(methyl 
vinyl ether-co-maleic acid) 
crosslinked with polyethylene 
glycol [291] (this is an open 
access article), (b) poly(vinyl 
alcohol) crosslinked-gelatin 
[289] (this is an open access 
article) and (c) HEMA-
crosslinked EGDMA (reprinted 
with permission from [290]  
Copyright © 2016, American 
Chemical Society). (d) A swol-
len hydrogel-forming MN post 
in vitro permeation study [291] 
(this is an open access article)
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macromolecules, such as ovalbumin and bevacizumab, in 
an in vivo study.
Hydrogel-forming MNs show some benefits when 
compared to the other type of MNs (solid, coated, hollow 
and dissolving). Firstly, as the drugs are not a component 
part of the MN matrix, it is possible to load a greater amount 
of drug into the associated drug-loaded reservoir than could 
be loaded into the MN arrays themselves. Consequently, this 
can lead to increased drug concentrations delivered into the 
skin. Secondly, following application, the swollen MN are 
removed intact from the skin; hence, there is no polymer 
deposition in the skin. Thirdly, hydrogel-forming MN only 
requires a one-step application process, leading to ease of 
administration [224]. These advantages have shown that 
hydrogel-forming MN can be considered as a promising 
strategy to enhance drug delivery across the skin.
Materials selection and manufacturing methods 
of microneedles
Initially, MNs were fabricated using microelectromechanical 
systems (MEMS) [49]. MEMS is a technology for creating 
microcomponents which combines mechanical and 
electrical aspects [293]. This technology was firstly used 
for manufacturing complex structures on a micron scale, 
particularly in the integrated circuit industry [294]. MEMS 
is known by distinctive names in different countries, such 
as micromachines in Asia or microsystems technology 
(MST) in Europe [295]. MEMS can be found in many 
products, such as airbag sensors, data storage, fiber optic 
networks, inkjet printer heads, projections screen and 
telecommunication devices [296]. MEMS are employed 
in different areas of application, including medical devices 
(implant and biosensor) and bio-MEMS (DNA sequencing 
instruments and microtitreplates) [297, 298].
The earliest form of MEMS is lithography. This 
technology was invented by Alois Senefelder in 1796 [293]. 
Lithography (originating from the Greek words meaning 
‘writing pattern in a stone’) were primarily used for printing 
text or artworks on paper or other materials. Then, in 1855, 
Alphonse Poitevin combined light with lithography based on 
his photography skill, and this was termed photolithography 
[299]. In 1955, for the first time, Andrus and Bond used a 
photoengraving technique (photolithography) for creating 
patterns on silicon wafers. In 1998, photolithography was 
then adapted for fabricating silicon MN [228]. Figure 20 
summarises the processes involved in the photolithographic 
technique.
Prior to the main process, it is imperative to ensure that 
the surface of silicon wafers is clean from dust particles or 
other organic materials. A solution composed of ammonium 
hydroxide–hydrogen peroxide–water (1:1:5, v/v) is used 
for removing organic contaminants and heavy metals 
[293]. Then, another solution consisting of hydrochloride 
acid–hydrogen peroxide–water (1:2:8, v/v) is employed for 
cleaning the surface from magnesium, aluminium and light 
alkali ions [293].
The first step in photolithography is exposing the silicon 
wafers to humidified oxygen or steam at high temperature 
(1000  °C) [49], as displayed in Fig.  20 (step 1). This 
process will grow a thin layer of silicon dioxide  (SiO2) 
on the surface of the silicon wafers, as represented by the 
blue layer in the second step in Fig. 20. This oxide layer 
tends to adsorb water molecules from the air and creates 
silanol groups (Si–OH) which result in poor adhesion 
of the photoresist materials [293]. Therefore, the wafers 
are preheated by placing in an oven (200–250 °C) for 
approximately 30 min to remove water molecules.
Following the growth of silicon dioxide and water 
removal, an adhesion promoter (hexamethyl disilazane) 
is added onto the wafer surface before the photosensitive/
photoresist mater ial is applied. A spin coating 
(1500–8000 rpm) process (step 3) is then performed to 
cover the silicon dioxide surface with the photoresist 
organic polymer. After the photoresist coat is formed 
(step 4), the wafers are soft baked at temperatures of 
75–100 °C to increase the adherence of each layer [49]. 
The next step is the UV lamp illumination (150–500 nm) 
of the photoresist layer through a mask (step 5). 
Subsequently, the mask pattern will be printed onto the 
photoresist layer and then the development process takes 
place.
In the positive resist, the exposed layer will become 
more soluble in the development solutions due to the 
weakening of chemical bonds within the resists [49]. 
Thus, the exposed part will dissolve in the development 
solution (sodium or potassium hydroxide) [293]. On the 
other hand, in the negative resist, the exposed part is 
chemically strengthened and its solubility decreased in the 
development solution [296]. The reduction of solubility 
may be caused by the increase of MW of the resist after 
exposing the UV light or the formation of insoluble 
products due to the photochemical transformation of 
the resist [293]. After the pattern is transferred and the 
development process is complete, an etching process of 
silicon dioxide is carried out. Etching is a method for 
removing the selected parts using based on the imaged 
photoresist after the pattern of the mask is transferred. 
The most common etching methods are wet etching (using 
chemical solution) and dry etching (using vapour gas) 
[296]. Following the etching process, the photoresist layer 
is then removed.
Besides silicon, other materials have also been explored 
for manufacturing MN. MN can be made of metals, such as 
titanium [240], stainless steel [247] and nickel [262]. Several 
methods are employed for fabricating metal MN, such as 
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electroplating, laser cutting and photochemical etching [300]. 
Metal MN can also be prepared by assembling stainless steel 
hypodermic needles on a poly(etheretherketone) mould 
[241]. Moreover, an infrared laser technique was also used 
for manufacturing this type of MN [247]. Despite the wide 
ranges of manufacturing methods and their promising ability 
in piercing the skin, metal MNs have some disadvantages, 
such as the possibility of immune-inflammatory responses 
at the application site and their use may cause an allergic 
reaction [49]. Thus, different materials were investigated for 
fabricating MN.
Polymer-based MNs, also known as polymeric MNs, 
have some benefits compared to the materials mentioned 
above. For instance, this type of MN is biocompatible, 
unlike silicon or metal [300]. Furthermore, numerous kinds 
of polymers have been studied for manufacturing polymeric 
MN, such as galactose [301], maltose [302], PLGA [231], 
carboxymethyl cellulose [303], poly(vinyl alcohol) [304], 
poly(vinyl pyrrolidone) [305], sodium hyaluronate [306], 
copolymer of methylvinylether and maleic anhydride [307], 
sodium alginate [308] and poly(acrylic acid) [309]. In 
addition, polymeric MN can be prepared using cost-effective 
Fig. 20  A schematic diagram 
illustrating all processes 
involved in photolithography
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and simple manufacturing methods, such as micromoulding-
based technique [300]. Poly(dimethylsiloxane) (PDMS) 
or silicone elastomer are the most common materials for 
making MN moulds [310]. To prepare the PDMS mould, 
a master structure of the mould is required. This master 
mould can be made of metal or silicon that is printed using 
a photolithography method. Specifically, metal master 
moulds are generally made by cutting from a solid block. 
Fig. 21  Schematic illustra-
tion describing a combination 
of micromoulding method 
and laser-based fabrication 
prior MN manufacturing. (a) 
Silicone elastomer is poured 
into the aluminium holder with 
a metal block inside it. (b) The 
aluminium container is filled 
with silicone elastomer, then 
this is centrifuged and cured 
overnight. (c) The dry silicone 
elastomer is demoulded from 
the aluminium holder. (d) A 
laser-engineered silicone sheet 
is placed and adhered onto the 
bottom part of the cast silicone 
elastomer. (e) Aerial and (f) 
cross-sectional view of adhered 
laser-engineered mould
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However, the master mould made of metal or silicon showed 
a limitation on the MN height and density [49].
In order to overcome the problems stated above, Donnelly 
et al. [307] combined the micromoulding method with a 
laser-engineered technique, as illustrated in Fig. 21. Laser 
technology utilises monochromatic light which can focus on 
a tiny spot [49]. Instead of printing the MN structure on the 
PDMS mould using a metal master mould, laser technology 
was used to create the MN structures, of relevant height, 
diameter and spacing, on silicone elastomer sheets. Thus, in 
this combination method, a laser-engineered silicone sheet is 
then adhered onto the bottom part of the PDMS or silicone 
elastomer by crosslinking. This system is then used as the 
master mould for manufacturing polymeric MN (Fig. 21a–f).
To then fabricate MN using these moulds, the selected 
polymers are dissolved in water to form an aqueous blend. 
A defined mass of this blend is then poured into the silicone 
mould. Then, the cast blend is centrifuged to fill the cavities 
and remove the bubbles during casting process. Following the 
centrifugation, the cast blend is then dried. The duration of 
drying is dependent on the type of polymer and composition 
of the formulation. After the MN are completely dry, they are 
carefully removed from the silicone mould, and the sidewalls 
are cut off using a heated scalpel blade, a process that can be 
operationalised in industrial manufacturing settings. These 
processes are summarised in Fig. 22a–f.
Current trend and prospective applications 
of microneedles
Since this delivery platform can be manufactured using a 
wide range of materials, scientists are currently intrigued to 
develop MN for several purposes, such as delivery of corona 
virus 2019 (Covid-19) vaccines, long acting treatment for 
human immunodeficiency virus (HIV), contraceptive 
products and for diagnostic purposes.
MN is one of many strategies which can be applied 
for enhancing delivery of drug both transdermally and 
intradermally. The ability of MN to pierce the skin and 
penetrate into the viable epidermis allows this drug to 
deliver macromolecules, including vaccines, into the 
skin. There are many immune cells in the skin, such as 
Langerhans cells, T cells, macrophages, lymphocytes, mast 
cells and dendritic cells [35]. The dendritic cells are antigen-
presenting cells which function to present the antigens to 
T cells and stimulate the immune system on the presented 
antigens [311]. This mechanism is beneficial for promoting 
immune system and prevents infections caused by viruses.
One virus of note which has emerged since late 2019 is 
COVID-19 [312]. This virus can cause harmful and deadly 
infections with mild until critical symptoms [313]. For 
instance, the number of people tested positive and deaths 
(with COVID-19 on the death certificate) in the United 
Kingdom (UK) up to 5 December 2020 was 1,705,971 
and 60,916, respectively [314]. In terms of positive cases 
and deaths globally until 6 December 2020, World Health 
Organization (WHO) has updated the data in their website 
and listed 65,870,030 of confirmed cases and 1,523,583 
number of deaths [315]. The number of positive cases and 
death have triggered researchers to develop vaccine for 
preventing the COVID-19 infections.
With respect to the development of MN for delivery 
of COVID-19 vaccine, Kim et al. [316] have successfully 
delivered recombinant coronavirus vaccines in mice. Shin 
et al. [317] have also proposed a degradable MN for COVID-
19 vaccine delivery system in their review article. They 
Fig. 22  Schematic representa-
tion of MN fabrication using 
micromoulding method which 
combined with laser-engineered 
silicone sheet. (a) An aqueous 
blend of polymer is poured onto 
the laser-engineered silicone 
sheet inside the green silicone 
elastomer mould. (b) The 
cast blend is then centrifuged. 
(c) Cross-sectional view of a 
silicone mould filled with aque-
ous polymeric blend during the 
drying process. (d) The dry MN 
is removed from the mould. (e) 
The sidewalls of the MN are cut 
off using a heated scalpel blade. 
(f) The MN following removal 
of the sidewalls
 Drug Delivery and Translational Research
1 3
mentioned that an ideal platform for delivering COVID-19 
vaccine should have simple integration system model which 
are able to be produced widely, not expensive and can be 
administrated with minimum instruction which reduces 
supervision [317]. In further work by Abbas et al. [318], the 
authors have reviewed the benefits of combining MN with 
nanoparticles for COVID-19 vaccine delivery. Since MN can 
be manufactured using biomaterials, this delivery platform 
has been projected as a prospective strategy to address 
challenges in tackling COVID-19 [319]. Another interesting 
application of MN has been reported by Chen et al. [320]. 
In their paper, they developed a flexible polymeric MN 
made of alginate polymer and used this MN as the heads of 
regular oropharyngeal swabs for improving the efficiency 
of sampling process during COVID-19 detection. These 
published sources have emerged the potential of MN for 
COVID-19 delivery and sampling process to reduce false 
negative results in COVID-19 detection.
MN technology has been shown to be useful in the 
delivery of long acting antiretroviral drugs. Long-acting 
delivery of antiretroviral (ARV) drugs is required for 
minimising the adverse effect of these drugs. When the 
drugs are administered orally for a long time, these may 
cause treatment fatigue which can result in poor patient 
compliance [271]. Nyaku et  al. [321] have previously 
published a summary of promising long acting delivery 
system for ARV drugs, including nanoformulations, 
microparticles and implants. Our research group (Donnelly 
et al.) have been developing a combination of nanoparticle 
formulations with dissolvable MN for a long acting delivery 
of ARV drugs. McCrudden et al. [271] have reported the 
use of dissolving MN for delivery of rilpivirine. They 
reported that the combination of rilpivirine-containing 
nanosuspension and dissolving MN could give mean plasma 
concentration in rats approximately 430 ng/ml at seventh 
day of treatment. In different study, McCrudden et al. [322] 
have also found that intravaginal delivery of rilpivirine using 
dissolving MN was able to give in vivo plasma concentration 
at approximately 115 ng/ml at the day 56 endpoint. In terms 
of MN acceptability for treatment of HIV, Moffatt et al. [323] 
has recently published the first paper which provided the 
insights of patients with HIV, healthcare professionals and 
members of lay public on the potential of MN for delivery 
of ARV drugs. Based on their research, it was known that 
both participants and respondents gave positive response on 
the MN application for treatment of HIV. Concerning the 
pharmacokinetic of ARV delivery using MN, Rajoli et al. 
[324] developed a physiological-based pharmacokinetic 
model for estimating the optimum dose regimen and release 
rate of MN containing cabotegravir and rilpivirine. Each of 
the studies mentioned outlines in detail a series of positive 
aspects for patients of MN delivery of ARV drugs. To 
maximise the use of MN for HIV treatment, it is imperative 
to give prior knowledge and education to the patients and 
healthcare professionals about the safety and the clinical 
applications of MN [323].
With respect to long-acting delivery of drugs using 
MN, this potential has been also used for delivery of 
contraceptive agents [325]. As previously discussed, 
the marketed transdermal products were mostly aimed 
to contraceptive agent delivery, such as estradiol, 
levonorgestrel and ethynyl estradiol. Transdermal delivery 
systems are used for minimising the drawbacks of some 
other delivery systems. For instances, transdermal 
delivery systems may overcome the associated drawbacks 
of oral dosage forms (not a long-acting system and poor 
patient adherence), injection (due to their invasiveness, 
pain experience and the need of personnel experts for 
administration) and implants (more invasive than injection 
and the requirement of trained healthcare professionals) 
[326–328]. Nevertheless, transdermal patches themselves 
have some associated drawbacks, such as the limitation 
of drugs to permeate across SC because this delivery 
system relies on passive diffusion [7]. These problems 
documented above may be overcome by using MN. 
MN technology can provide more benefits compared to 
conventional transdermal patches as they can penetrate the 
skin’s SC. MN can also be used for intradermal delivery 
of contraceptive agents providing long lasting effects once 
the drug has been deposited in the skin [7].
Published studies have demonstrated that MNs have 
much potential for delivery of long-acting contraceptives. 
Yavuz et al. [329] have investigated the silk fibroin-based 
MN for levonorgestrel sustained release. They found that 
MN containing levonorgestrel was able to deliver the drug 
up to 100 days. However, when the drug was formulated into 
microparticles before they were cast into MN, such system 
could deliver levonorgestrel for more than 1 year. A different 
type of MN was developed by Li et al. [327]. In their study, 
levonorgestrel-containing needles were attached onto 
effervescent MN patch which was able to leave the needles in 
the skin upon insertion. This system is easily administrated 
and can release the drug slowly up to more than 1 month. 
Dissolving MNs were also reported for delivery of different 
contraceptive hormones, such as etonogestrel [330]. 
Etonogestrel was previously formulated into microcrystal 
particles prior to MN casting. He et al. [330] have observed 
that dissolving MN could give similar in vivo bioavailability 
of etonogestrel when compared to intradermal injections. 
They proposed that MNs are prospective systems for 
sustained delivery of etonogestrel and an option to reduce 
the invasiveness of intradermal injection. A different 
research published by Li et al. [331] explored the use of 
2-layer MN for delivery of levonorgestrel in rats. This 
rapidly separable MN could provide sustained delivery of 
levonorgestrel up to 60 days. Brunie et al. [332] reported a 
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qualitative study on the acceptability of contraceptive MN. 
The investigation was conducted by an in-depth interview 
with women in India and Nigeria. They concluded that MN 
can be a promising approach for contraceptive purposes, 
however some aspects should be considered, including side 
effects, effectiveness and pricing of the MN. By altering and 
modifying the number of needles, patch size and the amount 
of drug formulated in MN, this technology could be a viable 
alternative option for delivering long-acting contraceptive 
hormones for women [325].
Besides the delivery function, MNs have also been 
investigated for therapeutic drug monitoring and bio-
sensing. This technology was considered as a minimally 
invasive monitoring method because it utilises the micron-
sized needles for taking the biological samples, such as 
skin interstitial fluid (ISF) or blood [333]. MNs are used for 
extracting skin ISF or blood samples from the skin [334], and 
an appropriate extraction method is employed prior analysis. 
For example, Rawson et al. [335] have published a paper 
about monitoring of phenoxymethylpenicillin concentration 
using hollow MN in healthy human volunteers. Moreover, 
Ito et  al. [336] used dissolving MN for monitoring the 
concentration of vancomycin in dermal ISF. Hydrogel-
forming MNs have also been reported for drug monitoring 
purposes, as previously reported by Caffarel-Salvador 
et al. [337], who used this type of MN for extracting and 
quantifying drug substances and glucose from skin.
The applications of MN which have been documented 
above have indicated that MN continue to be a promising 
technology for many purposes. It is not surprising, therefore, 
the World Economic Forum listed MN as one of ‘Top 10 
Emerging Technology of 2020’ [338]. However, they have 
also mentioned in their report that further researches are 
required for evaluating the factors which can affect the 
delivery and effectiveness of MN [338]. Moreover, for future 
consideration, there are some concerns which have to be 
standardised, such as the application process and patient’s 
prior knowledge and understanding of new MN technologies. 
Additionally, a programme of clinician education might be 
required for the clinical application of MN.
Conclusion
Transdermal delivery systems have been developed as a 
solution for overcoming problems associated with oral 
or injection dosage forms. There are many enhancement 
strategies that can be applied for improving transdermal 
delivery systems. Passive transdermal drug delivery 
technologies have been employed in the majority of 
marketed products. Nevertheless, this delivery system 
is limited to the small MW and hydrophobic drugs. 
The combination of energy driven methods, such as 
iontophoresis, with conventional transdermal patch 
 (Zecuity®) has given an alternative option for improving 
passive transdermal delivery system. Even though this 
approach sounds promising, this technology still cannot 
be used for delivering the macromolecules. Recent 
studies have shown that active method by piercing skin’s 
SC, namely MN, is one of promising approaches for 
delivery of various kind of drugs. By combining MN with 
conventional transdermal patches, it is more possible to 
deliver peptide/protein-based drugs via transdermal route. 
The applications of MN have been increasing since the 
first type of this delivery platform was developed in 1998. 
Published papers have also proved that MN can be used 
for improving delivery of drugs. Recently, MN have been 
successfully reported for many purposes, such as for 
delivering COVID-19 vaccines, long-acting delivery for 
HIV treatment and contraceptive hormones, and therapeutic 
drug monitoring. These have shown that MN technology 
have been a prospective strategy for improving transdermal 
delivery system. Furthermore, this delivery platform has 
been listed as one of ‘Top 10 Emerging Technologies 
of 2020’ by World Economic Forum. This endorsement 
by the World economic forum bolsters support for the 
rapid commercialisation of MN products currently under 
regulatory review and development. It is important that 
regulatory oversight is comprehensive for this emerging 
technology, and that all aspects of commercialisation 
are fully addressed to ensure MN technology can have a 
positive impact on patients and clinicians across the entire 
medial field. For instance, repeat bioequivalence studies 
must be conducted to ensure the safety, efficacy and 
validity of clinical phase data. Additionally, it is important 
that MN production and industrial scale-up is considered 
fully. This concern is often associated with the aseptic 
manufacture and large-scale fabrication processes. In 
addition, it is not surprising that advanced technology and 
hi-tech apparatus will be needed for the necessary quality 
assurance procedures. Consequently, this high-cost process 
will influence the price of the final product. Furthermore, 
before such a product can be considered for use in clinical 
settings, the relevant regulatory authorities must provide 
guidance on appropriate manufacturing conditions so that 
MN can be produced in a cost-effective manner.
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